Exclusive: UK biotech raises $33.1M to test CF drug that could work on top of standard of care
Enterprise Therapeutics closed a £26 million Series B round to fund a Phase IIa trial of its cystic fibrosis drug, which aims to significantly improve hydration and clear away the mucus that makes breathing difficult for these patients.
Panakes Partners led the round, along with participation from big-name existing investors like Versant Ventures, Novartis Venture Fund and Forbion.
The UK-based biotech plans to dose the first patient with ETD001, its lead drug, in a Phase IIa trial around Easter, CEO John Ford told Endpoints News, with the first batch of data set to come out in mid-2025. The trial, which will be conducted in the UK and Europe, has already secured regulatory approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.